Conference Coverage: EHA 2023 – Focus on Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS)
Expert perspectives on the latest therapeutic developments, treatment approaches, and implications for clinical decision-making regarding leukemia
June 10, 2023
Faculty Chair
Elias Jabbour, MD
MD Anderson Cancer Center, Houston, TX, USA
Faculty Members
Naval Daver, MD
MD Anderson Cancer Center, Houston, TX, USA
Guillermo Garcia-Manero, MD
MD Anderson Cancer Center, Houston, TX, USA
Alexander E. Perl, MD
Abramson Cancer Center, Penn Medicine, Philadelphia, PA, USA
Rami Komrokji, MD
Moffitt Cancer Center, Tampa, FL, USA
Jessica Altman, MD
Robert H. Lurie Comprehensive Cancer Center, Chicago, IL, USA
KEY TAKEAWAYS AND STRATEGIC INSIGHTS
- New Developments in First-line Treatment of MDS
- New Developments in Treatment of Relapsed/Refractory (R/R) MDS
- Advances in AML: Newly Diagnosed
- Advances in Acute Myeloid Leukemia (AML): Newly Diagnosed Elderly and/or Unfit
- Advances in AML: R/R AML
